Augment Health, Inc. has made a significant update regarding its private offering, as detailed in a recent SEC filing. The company reported a total offering amount of $800,000, with $370,000 already sold. This update is crucial as it highlights Augment Health's ongoing efforts to secure necessary funding.

Augment Health, Inc. is a corporation based in Nashville, Tennessee. The company was incorporated in Delaware and has been involved in various filings under the SEC. The latest filing, dated November 5, 2026, is a D/A submission, indicating an amendment to a previous filing.

The filing states, "Rule 506(b) provides a 'safer harbor' for a private offering." This suggests that Augment Health is leveraging regulatory provisions to enhance its fundraising efforts.

This update may affect various stakeholders, including potential investors and competitors in the manufacturing industry. The filing indicates that there are currently three investors involved, with no non-accredited investors participating in this offering.

Looking ahead, the filing does not specify what actions will follow this update. However, it underscores Augment Health's commitment to securing funding as it navigates the complexities of the manufacturing sector.

According to the filing, Augment Health, Inc. has not disclosed its revenue range, indicating a potential decline to disclose this information. This could suggest that the company is in a phase where financial details are being carefully managed or evaluated.

The offering is structured under Rule 506(b) of the SEC, which allows for the sale of securities to an unlimited number of accredited investors, but prohibits general solicitation or advertising. This regulatory framework is designed to provide a 'safer harbor' for private offerings, as noted in the filing.

The filing also indicates that the offering is not expected to last more than one year, with the date of the first sale recorded as October 5, 2026. This timeline may be important for potential investors considering their participation.

Furthermore, the filing specifies that there are currently no sales commissions or finders' fees associated with this offering, which may reflect Augment Health's strategy to maximize the proceeds from the offering.

Notably, the filing identifies Jared Meyers as the CEO and an executive officer of the company, who has signed off on the document, reinforcing his role in the company's leadership during this fundraising effort.

While the filing provides substantial information regarding the offering and the company's current status, it does not include specific details about how the funds raised will be utilized or any strategic plans moving forward.